Teh Seng Pharmaceutical MFG Co Ltd

Teh Seng Pharmaceutical MFG Co Ltd maintains a strong liquidity position, with cash and equivalents amounting to TWD 407.15 million, representing 36.5% of total assets. The company's debt-to-equity ratio is 0.07, indicating a conservative capital structure with minimal leverage. Operating cash flow of TWD 109.10 million supports ongoing operations and provides flexibility for future investments. Profitability metrics show a healthy balance between revenue and equity, with total equity of TWD 1,114.73 million and total liabilities of TWD 288.65 million. The company's long-term debt is limited to TWD 75.00 million, further reinforcing its financial stability. While specific profitability ratios such as ROIC or EBITDA margins are not provided, the low debt load and positive operating cash flow suggest a strong ability to generate returns on invested capital. The company's revenue is derived from a diverse product portfolio, including medicated plasters, facial masks, eye masks, biotechnology beauty products, and health foods. However, the financial snapshot does not provide segment-specific revenue breakdowns or geographic exposure details, making it difficult to assess concentration risk in specific markets or product lines. Teh Seng Pharmaceutical MFG Co Ltd reported revenue of TWD 845.19 million in the latest period. While no explicit growth trajectory is provided, the company's product diversification and international market presence suggest potential for expansion. The absence of capital expenditure data beyond the latest period limits the ability to assess long-term growth plans. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The low debt-to-equity ratio and strong cash position reduce financial leverage risk. Additionally, the absence of dilution risk suggests that the company is not currently issuing new shares to raise capital, preserving shareholder value. No recent events such as filings or transcripts are provided in the input data, limiting the ability to assess the company's recent strategic or operational developments. The company's financial disclosures are current, but further information would be needed to evaluate the impact of recent market or regulatory changes.